https://m2.mtmt.hu/ hun 2026-10-23 14:43 JournalArticle 32649994 ADMIN_APPROVED true 0 false 2026-10-22T03:55:59.626+0000 2026-04-28T15:16:08.333+0000 2022-02-06T13:17:39.989+0000 true 10015824 Fiáth Richárd /api/admin/10015824 Admin Fiáth Richárd (MTA TTK Idegtudomány, admin) true 10015824 2026-06-19T15:44:34.136+0000 2026-04-28T15:16:08.660+0000 true 10003132 Balázs András /api/admin/10003132 Admin Balázs András (MTMT Központ, admin) true 10003132 Admin 10065569 /api/admin/10065569 Pécsi Éva (MTMT Közp 2,3, admin) Pécsi Éva true true 2026-03-26T10:43:39.163+0000 true false true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle true 10000059 Article true 24 24 /api/publicationtype/24 PublicationType Folyóiratcikk 1 true 24 JournalArticle /api/subtype/10000059 Szakcikk SubType Szakcikk (Folyóiratcikk) 101 true 10000059 true 1 /api/category/1 Category Tudományos true 1 Petri, László true true /api/journal/1507 REVIEWED EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 true false 1507 false 1507 true 0223-5234 1768-3254 Journal FOREIGN 231 114163 114163 13 2022 Intrinsically disordered proteins (IDPs) play important roles in disease pathologies; however, their lack of defined stable 3D structures make traditional drug design strategies typically less effective against these targets. Based on promising results of targeted covalent inhibitors (TCIs) on challenging targets, we have developed a covalent design strategy targeting IDPs. As a model system we chose tau, an endogenous IDP of the central nervous system that is associated with severe neurodegenerative diseases via its aggregation. First, we mapped the tractability of available cysteines in tau and prioritized suitable warheads. Next, we introduced the selected vinylsulfone warhead to the non-covalent scaffolds of potential tau aggregation inhibitors. The designed covalent tau binders were synthesized and tested in aggregation models, and inhibited tau aggregation effectively. Our results revealed the usefulness of the covalent design strategy against therapeutically relevant IDP targets and provided promising candidates for the treatment of tauopathies. true 2022 true true true false true false GOLD 2026-10-22 true https://doi.org/10.1016/j.ejmech.2022.114163 19 0 19 19 1 19 19 19 15 19 19 19 19 19 0 0 19 19 19 19 0 8 8 Folyóiratcikk Journal Article 24 19 Könyvrészlet Chapter in Book 25 0 Könyv Book 23 0 Egyéb konferenciaközlemény Conference paper 31 0 Egyéb konferenciakötet Conference proceedings 32 0 Oltalmi formák Protection forms 26 0 Disszertáció Thesis 28 0 Egyéb Miscellaneous 29 0 Alkotás Achievement 22 0 Kutatási adat Research data 33 0 Folyóiratcikk Journal Article 24 0 0 0 Könyvrészlet Chapter in Book 25 0 0 0 Könyv Book 23 0 0 0 Egyéb konferenciaközlemény Conference paper 31 0 0 0 Egyéb konferenciakötet Conference proceedings 32 0 0 0 Oltalmi formák Protection forms 26 0 0 0 Disszertáció Thesis 28 0 0 0 Egyéb Miscellaneous 29 0 0 0 Alkotás Achievement 22 0 0 0 Kutatási adat Research data 33 0 0 0 2022 0 2 2 2 2 2023 0 2 2 2 2 2024 0 8 8 8 8 2025 0 3 3 3 3 2026 0 4 4 4 4 Q1 false 192,10053848 false false false 2022-02-07T11:21:23.689+0000 Biomolekuláris Önrendeződés (HRN TTK / AKI); Gyógyszerkémiai Kutatócsoport (HRN TTK / SZKI); Mesterséges Transzporterek Kutatócsoport (HRN TTK / AKI); Műszercentrum (TTK); Plazmakémiai Kutatócsoport (HRN TTK / AKI); Összehasonlító Pszichofiziológiai Kutatócsoport (HRN TTK / KPI) 11 84 6 13 0 true 10065569 Language 10002 /api/language/10002 Angol Angol English true 2 true PersonAuthorship 100447026 /api/authorship/100447026 Petri, László [Petri, László (szerves kémia, gy...), szerző] Gyógyszerkémiai Kutatócsoport (HRN TTK / SZKI) 1 0.077 true false false Author 10053848 /api/author/10053848 Petri László (szerves kémia, gyógyszerkémia) Petri László true 10053848 true Petri László true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447027 /api/authorship/100447027 Ábrányi-Balogh, Péter* [Ábrányi-Balogh, Péter (szerves kémia), szerző] Gyógyszerkémiai Kutatócsoport (HRN TTK / SZKI) 2 0.077 true false false Author 10042926 /api/author/10042926 Ábrányi-Balogh Péter (szerves kémia) Ábrányi-Balogh Péter true 10042926 true Ábrányi-Balogh Péter true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447028 /api/authorship/100447028 Vagrys, Darius 3 0.07692308 false false false Vagrys Darius true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447029 /api/authorship/100447029 Imre, Tímea [Imre, Timea (Tömegspektrometria), szerző] Műszercentrum (TTK) 4 0.07692308 false false false Author 10014805 /api/author/10014805 Imre Timea (Tömegspektrometria) Imre Timea true 10014805 true Imre Tímea true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447030 /api/authorship/100447030 Varró, Nikolett [Varró, Nikolett (Mesterséges trans...), szerző] Mesterséges Transzporterek Kutatócsoport (HRN TTK / AKI) 5 0.077 false false false Author 10065032 /api/author/10065032 Varró Nikolett (Mesterséges transzporterek, szerves kémia) Varró Nikolett true 10065032 true Varró Nikolett true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447031 /api/authorship/100447031 Mándity, István [Mándity, István (Gyógyszerkémia, g...), szerző] Mesterséges Transzporterek Kutatócsoport (HRN TTK / AKI) 6 0.077 false false false Author 10022837 /api/author/10022837 Mándity István (Gyógyszerkémia, gyógyszerkutatás) Mándity István true 10022837 true Mándity István true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447032 /api/authorship/100447032 Rácz, Anita [Rácz, Anita (kémia, kemometria...), szerző] Plazmakémiai Kutatócsoport (HRN TTK / AKI) 7 0.077 false false false Author 10044714 /api/author/10044714 Rácz Anita (kémia, kemometria, kemoinformatika) Rácz Anita true 10044714 true Rácz Anita true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447033 /api/authorship/100447033 Wittner, Lucia [Wittner, Lucia (Idegtudomány), szerző] Összehasonlító Pszichofiziológiai Kutatócsoport (HRN TTK / KPI) 8 0.077 false false false Author 10001192 /api/author/10001192 Wittner Lucia (Idegtudomány) Wittner Lucia true 10001192 true Wittner Lucia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447034 /api/authorship/100447034 Tóth, Kinga [Tóth, Kinga (Neurobiológia), szerző] Összehasonlító Pszichofiziológiai Kutatócsoport (HRN TTK / KPI) 9 0.077 false false false Author 192 /api/author/192 Tóth Kinga (Neurobiológia) Tóth Kinga true 192 true Tóth Kinga true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447035 /api/authorship/100447035 Tóth, Estilla Zsófia [Tóth, Estilla Zsófia (neurobiológia), szerző] Összehasonlító Pszichofiziológiai Kutatócsoport (HRN TTK / KPI) 10 0.077 false false false Author 10055720 /api/author/10055720 Tóth Estilla Zsófia (neurobiológia) Tóth Estilla Zsófia true 10055720 true Tóth Estilla Zsófia true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447036 /api/authorship/100447036 Juhász, Tünde [Juhász, Tünde (Enzimológia), szerző] Biomolekuláris Önrendeződés (HRN TTK / AKI) 11 0.077 false false false Author 10019488 /api/author/10019488 Juhász Tünde (Enzimológia) Juhász Tünde true 10019488 true Juhász Tünde true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447037 /api/authorship/100447037 Davis, Ben 12 0.07692308 false false false Davis Ben true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PersonAuthorship 100447038 /api/authorship/100447038 Keserű, György Miklós ✉ [Keserű, György Miklós (Gyógyszerkémia, g...), szerző] Gyógyszerkémiai Kutatócsoport (HRN TTK / SZKI) 13 0.077 false true true Author 10001451 /api/author/10001451 Keserű György Miklós (Gyógyszerkémia, gyógyszertervezés) Keserű György Miklós true 10001451 true Keserű György Miklós true false false AuthorshipType 1 /api/authorshiptype/1 Szerző 0 true 0 true false true PublicationIdentifier 20540296 /api/publicationidentifier/20540296 DOI: 10.1016/j.ejmech.2022.114163 PlainSource 6 /api/publicationsource/6 DOI PublicationSourceType 10001 /api/publicationsourcetype/10001 DOI true true true DOI DOI https://doi.org/@@@ true true 6 true GOLD true IDENTICAL 10.1016/j.ejmech.2022.114163 https://doi.org/10.1016/j.ejmech.2022.114163 false true PublicationIdentifier 20879134 /api/publicationidentifier/20879134 WoS: 000765974800006 PlainSource 1 /api/publicationsource/1 WoS PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true WoS WoS https://www.webofscience.com/wos/woscc/full-record/@@@ true true 1 true IDENTICAL 000765974800006 https://www.webofscience.com/wos/woscc/full-record/000765974800006 false true PublicationIdentifier 25752061 /api/publicationidentifier/25752061 REAL: 189225 SwordSource 36 /api/publicationsource/36 REAL PublicationSourceType 10007 /api/publicationsourcetype/10007 Repozitórium true true true REAL REAL https://real.mtak.hu/@@@ true true 36 true GOLD true 189225 https://real.mtak.hu/189225 false true PublicationIdentifier 22960424 /api/publicationidentifier/22960424 Scopus: 85124021805 PlainSource 3 /api/publicationsource/3 Scopus PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true Scopus Scopus http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@ true true 3 true IDENTICAL 85124021805 http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124021805 true true PublicationIdentifier 23113916 /api/publicationidentifier/23113916 PubMed: 35131537 PlainSource 17 /api/publicationsource/17 PubMed PublicationSourceType 10003 /api/publicationsourcetype/10003 Indexelő adatbázis false true true PubMed PubMed http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract true true 17 true IDENTICAL 35131537 http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35131537&dopt=Abstract false true PublicationIdentifier 31492801 /api/publicationidentifier/31492801 Egyéb URL: https://linkinghub.elsevier.com/retrieve/pii/S0223523422000654 PlainSource 40 /api/publicationsource/40 Egyéb URL PublicationSourceType 10006 /api/publicationsourcetype/10006 Link true true true Egyéb URL Other URL @@@ true true 40 true IDENTICAL https://linkinghub.elsevier.com/retrieve/pii/S0223523422000654 https://linkinghub.elsevier.com/retrieve/pii/S0223523422000654 false true Classification 10293 /api/classification/10293 Kémiai tudományok true true SjrRating 11321063 /api/sjrrating/11321063 sjr:Q1 (2022) Scopus - Drug Discovery EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 27 0.24 journal RatingType 10002 /api/ratingtype/10002 sjr sjr true true ClassificationExternal 3002 /api/classificationexternal/3002 Scopus - Drug Discovery true 3002 true Q1 DIRECT true true Reference 27593860 /api/reference/27593860 1. Bauer 2015: Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies., Drug Discov. Today, 20, p. 1061, DOI: 10.1016/j.drudis.2015.05.005 1 10.1016/j.drudis.2015.05.005 false true Reference 27593861 /api/reference/27593861 2. Singh 2012: Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research., Carcinogenesis, 33, p. 1833, DOI: 10.1093/carcin/bgs216 2 10.1093/carcin/bgs216 false true Reference 27593862 /api/reference/27593862 3. Baillie 2016: Targeted covalent inhibitors for drug design., Angew. Chem. Int. Ed., 55, p. 13408, DOI: 10.1002/anie.201601091 3 10.1002/anie.201601091 false true Reference 27593863 /api/reference/27593863 4. Ghosh 2019: Covalent inhibition in drug discovery., ChemMedChem, 14, p. 889, DOI: 10.1002/cmdc.201900107 4 10.1002/cmdc.201900107 false true Reference 27593864 /api/reference/27593864 5. Shannon 2015: Covalent protein modification: the current landscape of residue-specific electrophiles., Curr. Opin. Chem. Biol., 24, p. 18, DOI: 10.1016/j.cbpa.2014.10.021 5 10.1016/j.cbpa.2014.10.021 false true Reference 27593865 /api/reference/27593865 6. Li 2019: Targeting protein-protein interaction with covalent small-molecule inhibitors., Curr. Top. Med. Chem., 19, p. 1872, DOI: 10.2174/1568026619666191011163410 6 10.2174/1568026619666191011163410 false true Reference 27593866 /api/reference/27593866 7. Nussinov 2015: The design of covalent allosteric drugs., Annu. Rev. Pharmacol. Toxicol., 55, p. 249, DOI: 10.1146/annurev-pharmtox-010814-124401 7 10.1146/annurev-pharmtox-010814-124401 false true Reference 27593867 /api/reference/27593867 8. Chen 2020: Transcription factor inhibition: lessons learned and emerging targets., Trends Mol. Med., 26, p. 508, DOI: 10.1016/j.molmed.2020.01.004 8 10.1016/j.molmed.2020.01.004 false true Reference 27593868 /api/reference/27593868 9. Orgován 2020: Small molecule inhibitors of RAS proteins with oncogenic mutations., Cancer Metastasis Rev., 39, p. 1107, DOI: 10.1007/s10555-020-09911-9 9 10.1007/s10555-020-09911-9 false true Reference 27593869 /api/reference/27593869 10. Tompa 2002: Intrinsically unstructured proteins., Trends Biochem. Sci., 27, p. 527, DOI: 10.1016/S0968-0004(02)02169-2 10 10.1016/S0968-0004(02)02169-2 false true Reference 27593870 /api/reference/27593870 11. van der Lee 2014: Classification of intrinsically disordered regions and proteins., Chem. Rev., 114, p. 6589, DOI: 10.1021/cr400525m 11 10.1021/cr400525m false true Reference 27593871 /api/reference/27593871 12. Nguyen 2020: Targeting an Intrinsically Disordered Protein by Covalent Modificationp. 835 12 false true Reference 27593872 /api/reference/27593872 13. Orr 2017: A brief overview of tauopathy: causes, consequences, and therapeutic strategies., Trends Pharmacol. Sci., 38, p. 637, DOI: 10.1016/j.tips.2017.03.011 13 10.1016/j.tips.2017.03.011 false true Reference 27593873 /api/reference/27593873 14. Iqbal 2010: Tau in alzheimer disease and related tauopathies., Curr. Alzheimer Res., 7, p. 656, DOI: 10.2174/156720510793611592 14 10.2174/156720510793611592 false true Reference 27593874 /api/reference/27593874 15. Pîrşcoveanu 2017: Tau protein in neurodegenerative diseases - a review., Rom. J. Morphol. Embryol., 58, p. 1141 15 false true Reference 27593875 /api/reference/27593875 16. Lippens 2007: Tau aggregation in Alzheimer's disease., Prion, 1, p. 21, DOI: 10.4161/pri.1.1.4055 16 10.4161/pri.1.1.4055 false true Reference 27593876 /api/reference/27593876 17. Tortosa 2011: Microtubule-associated protein 1B (MAP1B) is required for dendritic spine development and synaptic maturation., J. Biol. Chem., 286, p. 40638, DOI: 10.1074/jbc.M111.271320 17 10.1074/jbc.M111.271320 false true Reference 27593877 /api/reference/27593877 18. von Bergen 2001: Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local β-structure., J. Biol. Chem., 276, p. 48165, DOI: 10.1074/jbc.M105196200 18 10.1074/jbc.M105196200 false true Reference 27593878 /api/reference/27593878 19. von Bergen 2000: Assembly of tau protein into alzheimer paired helical filaments depends on a local sequence motif (306VQIVYK311) forming Beta structure., Proc. Natl. Acad. Sci. Unit. States Am., 97, p. 5129, DOI: 10.1073/pnas.97.10.5129 19 10.1073/pnas.97.10.5129 false true Reference 27593879 /api/reference/27593879 20. Gustke 1994: Domains of tau protein and interactions with microtubules., Biochemistry, 33, p. 9511, DOI: 10.1021/bi00198a017 20 10.1021/bi00198a017 false true Reference 27593880 /api/reference/27593880 21. Vagrys 2020: Exploring IDP–ligand interactions: tau K18 as a test case., Int. J. Mol. Sci., 21, p. 5257, DOI: 10.3390/ijms21155257 21 10.3390/ijms21155257 false true Reference 27593881 /api/reference/27593881 22. Gustke 1994: Domains of tau protein and interactions with microtubules., Biochemistry, 33, p. 9511, DOI: 10.1021/bi00198a017 22 10.1021/bi00198a017 false true Reference 27593882 /api/reference/27593882 23. Yao 2013: Molecular hairpin: a possible model for inhibition of tau aggregation by tannic acid., Biochemistry, 52, p. 1893, DOI: 10.1021/bi400240c 23 10.1021/bi400240c false true Reference 27593883 /api/reference/27593883 24. Bulic 2013: Progress and developments in tau aggregation inhibitors for alzheimer disease., J. Med. Chem., 56, p. 4135, DOI: 10.1021/jm3017317 24 10.1021/jm3017317 false true Reference 27593884 /api/reference/27593884 25. Silva 2020: Two Targets for Dementiap. 1 25 false true Reference 27593885 /api/reference/27593885 26. Ingham 2021: Fungally derived isoquinoline demonstrates inducer-specific tau aggregation inhibition., Biochemistry, 60, p. 1658, DOI: 10.1021/acs.biochem.1c00111 26 10.1021/acs.biochem.1c00111 false true Reference 27593886 /api/reference/27593886 27. Malafaia 2021: Amyloid-β and tau aggregation dual-inhibitors: a synthetic and structure-activity relationship focused review., Eur. J. Med. Chem., 214, p. 113209, DOI: 10.1016/j.ejmech.2021.113209 27 10.1016/j.ejmech.2021.113209 false true Reference 27593887 /api/reference/27593887 28. Paranjape 2014: Inhibition of tau aggregation by three Aspergillus nidulans secondary metabolites: 2,ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde., Planta Med., 80, p. 77, DOI: 10.1055/s-0033-1360180 28 10.1055/s-0033-1360180 false true Reference 27593888 /api/reference/27593888 29. Soeda 2015: Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups., Nat. Commun., 6, p. 10216, DOI: 10.1038/ncomms10216 29 10.1038/ncomms10216 false true Reference 27593889 /api/reference/27593889 30. Haque 2014: Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking., Amyloid, 21, p. 185, DOI: 10.3109/13506129.2014.929103 30 10.3109/13506129.2014.929103 false true Reference 27593890 /api/reference/27593890 31. George 2013: Interaction of cinnamaldehyde and epicatechin with tau: implications of beneficial effects in modulating Alzheimer's disease pathogenesis., J. Alzheim. Dis., 36, p. 21, DOI: 10.3233/JAD-122113 31 10.3233/JAD-122113 false true Reference 27593891 /api/reference/27593891 32. González 2021: The fumarprotocetraric acid inhibits tau covalently, avoiding cytotoxicity of aggregates in cells., Molecules, 26, p. 3760, DOI: 10.3390/molecules26123760 32 10.3390/molecules26123760 false true Reference 27593892 /api/reference/27593892 33. Dominguez-Meijide 2020: Pharmacological modulators of tau aggregation and spreading., Brain Sci., 10, p. 858, DOI: 10.3390/brainsci10110858 33 10.3390/brainsci10110858 false true Reference 27593893 /api/reference/27593893 34. González-Bello 2016: Designing irreversible inhibitors-worth the effort?., ChemMedChem, 11, p. 22, DOI: 10.1002/cmdc.201500469 34 10.1002/cmdc.201500469 false true Reference 27593894 /api/reference/27593894 35. Smith 2009: Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins., J. Med. Chem., 52, p. 225, DOI: 10.1021/jm800498e 35 10.1021/jm800498e false true Reference 27593895 /api/reference/27593895 36. Fell 2020: Identification of the clinical development candidate MRTX849 , a covalent KRAS G12C inhibitor for the treatment of cancer., J. Med. Chem., 63, p. 6679, DOI: 10.1021/acs.jmedchem.9b02052 36 10.1021/acs.jmedchem.9b02052 false true Reference 27593896 /api/reference/27593896 37. Weerapana 2010: Quantitative reactivity profiling predicts functional cysteines in proteomes., Nature, 468, p. 790, DOI: 10.1038/nature09472 37 10.1038/nature09472 false true Reference 27593897 /api/reference/27593897 38. McGregor 2017: Expanding the scope of electrophiles capable of targeting K-ras oncogenes., Biochemistry, 56, p. 3178, DOI: 10.1021/acs.biochem.7b00271 38 10.1021/acs.biochem.7b00271 false true Reference 27593898 /api/reference/27593898 39. Gersch 2012: Electrophilic natural products and their biological targets., Nat. Prod. Rep., 29, p. 659, DOI: 10.1039/c2np20012k 39 10.1039/c2np20012k false true Reference 27593899 /api/reference/27593899 40. Du 2017: CBinderDB: a covalent binding agent database., Bioinformatics, 33, p. 1258 40 false true Reference 27593900 /api/reference/27593900 41. Ábrányi-Balogh 2018: A road map for prioritizing warheads for cysteine targeting covalent inhibitors., Eur. J. Med. Chem., 160, p. 94, DOI: 10.1016/j.ejmech.2018.10.010 41 10.1016/j.ejmech.2018.10.010 false true Reference 27593901 /api/reference/27593901 42. Keeley 2020: Covalent fragment libraries in drug discovery., Drug Discov. Today, 25, p. 983, DOI: 10.1016/j.drudis.2020.03.016 42 10.1016/j.drudis.2020.03.016 false true Reference 27593902 /api/reference/27593902 43. Petri 2021: Assessment of tractable cysteines for covalent targeting by screening covalent fragments., Chembiochem, 22, p. 743, DOI: 10.1002/cbic.202000700 43 10.1002/cbic.202000700 false true Reference 27593903 /api/reference/27593903 44. Petri 2020: An electrophilic warhead library for mapping the reactivity and accessibility of tractable cysteines in protein kinases., Eur. J. Med. Chem., 207, p. 112836, DOI: 10.1016/j.ejmech.2020.112836 44 10.1016/j.ejmech.2020.112836 false true Reference 27593904 /api/reference/27593904 45. Hoch 2018: Cysteine-reactive probes and their use in chemical proteomics., Chem. Commun., 54, p. 4501, DOI: 10.1039/C8CC01485J 45 10.1039/C8CC01485J false true Reference 27593905 /api/reference/27593905 46. Bulic 2007: Rhodanine-based tau aggregation inhibitors in cell models of tauopathy., Angew. Chem. Int. Ed., 46, p. 9215, DOI: 10.1002/anie.200704051 46 10.1002/anie.200704051 false true Reference 27593906 /api/reference/27593906 47. Falcon 2019: Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules., Nature, 568, p. 420, DOI: 10.1038/s41586-019-1026-5 47 10.1038/s41586-019-1026-5 false true Reference 27593907 /api/reference/27593907 48. Seidler 2018: Structure-based inhibitors of tau aggregation., Nat. Chem., 10, p. 170, DOI: 10.1038/nchem.2889 48 10.1038/nchem.2889 false true Reference 27593908 /api/reference/27593908 49. Bhattacharya 2001: Role of cysteine-291 and cysteine-322 in the polymerization of human tau into alzheimer-like filaments., Biochem. Biophys. Res. Commun., 285, p. 20, DOI: 10.1006/bbrc.2001.5116 49 10.1006/bbrc.2001.5116 false true Reference 27593909 /api/reference/27593909 50. Bulic 2007: Rhodanine-based tau aggregation inhibitors in cell models of tauopathy., Angew. Chem. Int. Ed., 46, p. 9215, DOI: 10.1002/anie.200704051 50 10.1002/anie.200704051 false true Reference 27593910 /api/reference/27593910 51. Giorgetti 2018: Targeting amyloid aggregation: an overview of strategies and mechanisms., Int. J. Mol. Sci., 19, p. 2677, DOI: 10.3390/ijms19092677 51 10.3390/ijms19092677 false true Reference 27593911 /api/reference/27593911 52. Chen 2013: Fusion protein linkers: property, design and functionality., Adv. Drug Deliv. Rev., 65, p. 1357, DOI: 10.1016/j.addr.2012.09.039 52 10.1016/j.addr.2012.09.039 false true Reference 27593912 /api/reference/27593912 53. Arai 2001: Design of the linkers which effectively separate domains of a bifunctional fusion protein., Protein Eng. Des. Sel., 14, p. 529, DOI: 10.1093/protein/14.8.529 53 10.1093/protein/14.8.529 false true Reference 27593913 /api/reference/27593913 54. Chen 2016: Structural characterization of cross-linked species in trastuzumab emtansine (kadcyla)., Bioconjugate Chem., 27, p. 2037, DOI: 10.1021/acs.bioconjchem.6b00316 54 10.1021/acs.bioconjchem.6b00316 false true Reference 27593914 /api/reference/27593914 55. Zhao 2008: Increasing the homogeneity, stability and activity of human serum albumin and interferon-a2b fusion protein by linker engineering., Protein Expr. Purif., 61, p. 73, DOI: 10.1016/j.pep.2008.04.013 55 10.1016/j.pep.2008.04.013 false true Reference 27593915 /api/reference/27593915 56. Atherton 1985: Solid phase peptide synthesis using N α -fluorenylmethoxycarbonylamino acid pentafluorophenyl esters., J. Chem. Soc., Chem. Commun., 3, p. 165, DOI: 10.1039/C39850000165 56 10.1039/C39850000165 false true Reference 27593916 /api/reference/27593916 57. Seidler 2018: Structure-based inhibitors of tau aggregation., Nat. Chem., 10, p. 170, DOI: 10.1038/nchem.2889 57 10.1038/nchem.2889 false true Reference 27593917 /api/reference/27593917 58. Shammas 2015: A mechanistic model of tau amyloid aggregation based on direct observation of oligomers., Nat. Commun., 6, p. 7025, DOI: 10.1038/ncomms8025 58 10.1038/ncomms8025 false true Reference 27593918 /api/reference/27593918 59. Gade Malmos 2017: ThT 101: a primer on the use of Thioflavin T to investigate amyloid formation., Amyloid, 24, p. 1, DOI: 10.1080/13506129.2017.1304905 59 10.1080/13506129.2017.1304905 false true Reference 27593919 /api/reference/27593919 60. Biernat 1993: Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding., Neuron, 11, p. 153, DOI: 10.1016/0896-6273(93)90279-Z 60 10.1016/0896-6273(93)90279-Z false true Reference 27593920 /api/reference/27593920 61. Huseby 2016: Analyzing Tau Aggregation with Electron Microscopyp. 101 61 false true Reference 27593921 /api/reference/27593921 62. Al-Riyami 2013: Designing anti-inflammatory drugs from parasitic worms: a synthetic small molecule analogue of the acanthocheilonema viteae product ES-62 prevents development of collagen-induced arthritis., J. Med. Chem., 56, p. 9982, DOI: 10.1021/jm401251p 62 10.1021/jm401251p false true Reference 27593922 /api/reference/27593922 63. Alonso 2003: π-Deficient 2-(Arylsulfonyl)Ethyl Esters as Protecting Groups for Carboxylic Acids 63 false true Reference 27593923 /api/reference/27593923 64. Córdova-Rivas 2020: Differential proliferation effect of the newly synthesized valine, tyrosine and tryptophan–naphthoquinones in immortal and tumorigenic cervical cell lines., Molecules, 25, p. 2058, DOI: 10.3390/molecules25092058 64 10.3390/molecules25092058 false true Reference 27593924 /api/reference/27593924 65. Friedrich 1952: Verfahren Zur Herstellung von AEthensulfarylamidenp. DE832149 65 false true /api/publication/32649994 Petri László et al. A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors. (2022) EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 0223-5234 1768-3254 231<div class="JournalArticle Publication long-list"> <div class="authors"> <img title="Forrásközlemény" style="float: left" src="/frontend/resources/grid/publication-core-icon.png"> <img title="Idézőközlemény" style="float: left" src="/frontend/resources/grid/publication-citation-icon.png"> <div class="autype autype0"> <span class="author-name" mtid="10053848"><a href="/gui2/?type=authors&mode=browse&sel=10053848" target="_blank">Petri László (<span class="authorship-author-name">Petri László</span> <span class="authorAux-mtmt"> szerves kémia, gyógyszerkémia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Szerves Kémiai Intézet">SZKI</span>/Gyógyszerkémiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10042926"><a href="/gui2/?type=authors&mode=browse&sel=10042926" target="_blank">Ábrányi-Balogh Péter^* (<span class="authorship-author-name">Ábrányi-Balogh Péter</span> <span class="authorAux-mtmt"> szerves kémia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Szerves Kémiai Intézet">SZKI</span>/Gyógyszerkémiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Vagrys Darius </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10014805"><a href="/gui2/?type=authors&mode=browse&sel=10014805" target="_blank">Imre Tímea (<span class="authorship-author-name">Imre Timea</span> <span class="authorAux-mtmt"> Tömegspektrometria</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/Műszercentrum</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10065032"><a href="/gui2/?type=authors&mode=browse&sel=10065032" target="_blank">Varró Nikolett (<span class="authorship-author-name">Varró Nikolett</span> <span class="authorAux-mtmt"> Mesterséges transzporterek, szerves kémia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Anyag- és Környezetkémiai Intézet">AKI</span>/Mesterséges Transzporterek Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10022837"><a href="/gui2/?type=authors&mode=browse&sel=10022837" target="_blank">Mándity István (<span class="authorship-author-name">Mándity István</span> <span class="authorAux-mtmt"> Gyógyszerkémia, gyógyszerkutatás</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Anyag- és Környezetkémiai Intézet">AKI</span>/Mesterséges Transzporterek Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10044714"><a href="/gui2/?type=authors&mode=browse&sel=10044714" target="_blank">Rácz Anita (<span class="authorship-author-name">Rácz Anita</span> <span class="authorAux-mtmt"> kémia, kemometria, kemoinformatika</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Anyag- és Környezetkémiai Intézet">AKI</span>/Plazmakémiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001192"><a href="/gui2/?type=authors&mode=browse&sel=10001192" target="_blank">Wittner Lucia (<span class="authorship-author-name">Wittner Lucia</span> <span class="authorAux-mtmt"> Idegtudomány</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Kognitív Idegtudományi és Pszichológiai Intézet">KPI</span>/Összehasonlító Pszichofiziológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="192"><a href="/gui2/?type=authors&mode=browse&sel=192" target="_blank">Tóth Kinga (<span class="authorship-author-name">Tóth Kinga</span> <span class="authorAux-mtmt"> Neurobiológia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Kognitív Idegtudományi és Pszichológiai Intézet">KPI</span>/Összehasonlító Pszichofiziológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10055720"><a href="/gui2/?type=authors&mode=browse&sel=10055720" target="_blank">Tóth Estilla Zsófia (<span class="authorship-author-name">Tóth Estilla Zsófia</span> <span class="authorAux-mtmt"> neurobiológia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Kognitív Idegtudományi és Pszichológiai Intézet">KPI</span>/Összehasonlító Pszichofiziológiai Kutatócsoport</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10019488"><a href="/gui2/?type=authors&mode=browse&sel=10019488" target="_blank">Juhász Tünde (<span class="authorship-author-name">Juhász Tünde</span> <span class="authorAux-mtmt"> Enzimológia</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Anyag- és Környezetkémiai Intézet">AKI</span>/Biomolekuláris Önrendeződés</span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" >Davis Ben </span> ;&nbsp;&nbsp;&nbsp; <span class="author-name" mtid="10001451"><a href="/gui2/?type=authors&mode=browse&sel=10001451" target="_blank">Keserű György Miklós ✉ (<span class="authorship-author-name">Keserű György Miklós</span> <span class="authorAux-mtmt"> Gyógyszerkémia, gyógyszertervezés</span>) </a> </span> <span class="author-affil"><span title="Természettudományi Kutatóközpont">TTK</span>/<span title="Szerves Kémiai Intézet">SZKI</span>/Gyógyszerkémiai Kutatócsoport</span> </div> </div> <div class="title"><a href="/gui2/?mode=browse&params=publication;32649994" target="_blank">A covalent strategy to target intrinsically disordered proteins: Discovery of novel tau aggregation inhibitors</a></div> <div> <span class="journal-title">EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY</span> <span class="journal-issn">(<a target="_blank" href="https://portal.issn.org/resource/ISSN/0223-5234">0223-5234</a> <a target="_blank" href="https://portal.issn.org/resource/ISSN/1768-3254">1768-3254</a>)</span>: <span class="journal-volume">231</span> <span class="page"> Paper 114163. 13 p. </span> <span class="year">(2022)</span> </div> <div class="pub-footer"> <span class="language" xmlns="http://www.w3.org/1999/html">Nyelv: Angol | </span> <span class="identifiers"> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:blue" title="10.1016/j.ejmech.2022.114163" target="_blank" href="https://doi.org/10.1016/j.ejmech.2022.114163"> DOI </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="000765974800006" target="_blank" href="https://www.webofscience.com/wos/woscc/full-record/000765974800006"> WoS </a> </span> <span class="id identifier oa_GOLD" title=" Gold "> <a style="color:black" title="189225" target="_blank" href="https://real.mtak.hu/189225"> REAL </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="85124021805" target="_blank" href="http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85124021805"> Scopus </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="35131537" target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35131537&dopt=Abstract"> PubMed </a> </span> <span class="id identifier oa_none" title="none"> <a style="color:blue" title="https://linkinghub.elsevier.com/retrieve/pii/S0223523422000654" target="_blank" href="https://linkinghub.elsevier.com/retrieve/pii/S0223523422000654"> Egyéb URL </a> </span> </span> <OnlyViewableByAuthor><div class="ratings"> <div class="journal-subject">Folyóirat szakterülete: Scopus - Drug Discovery&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Medicine (miscellaneous)&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Organic Chemistry&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> <div class="journal-subject">Folyóirat szakterülete: Scopus - Pharmacology&nbsp;&nbsp;&nbsp;SJR indikátor:&nbsp;Q1</div> </div></OnlyViewableByAuthor> <div class="publication-citation" style="margin-left: 0.5cm;"> <span title="Nyilvános idézőközlemények összesen, említések nélkül" class="citingPub-count">Nyilvános idéző összesen: 19</span> | Független: 19 | Függő: 0 | Nem jelölt: 0 | WoS jelölt: 19 | Scopus jelölt:&nbsp;15 | WoS/Scopus jelölt:&nbsp;19 | DOI jelölt:&nbsp;19 </div> <div class="publication-citation"> <a target="_blank" href="/api/publication?cond=citations.related;eq;32649994&sort=publishedYear,desc&sort=title"> Idézett közlemények száma: 8 </a> </div> <div class="mtid"><span class="long-pub-mtid">Közlemény: 32649994</span> | <span class="status-data status-ADMIN_APPROVED"> Admin láttamozott </span> Forrás Idéző | <span class="type-subtype">Folyóiratcikk ( Szakcikk ) </span> | <span class="pub-category">Tudományos</span> | <span class="publication-sourceOfData">kézi felvitel</span> </div> <div class="lastModified">Utolsó módosítás: 2026.04.28. 17:16 Balázs András (MTMT Központ, admin) </div> <div class="lockedBy">Központi kezelésű 2026.03.26. 11:43 Pécsi Éva (MTMT Közp 2,3, admin) </div> </div></div>